" There is reason to be optimistic about the future of therapy for
patients with recurrent ovarian cancer. Inhibition of Wee-1 may target
the universal
p53 aberrations observed in high-grade serous
cancers, and Wee-1 inhibitors are being developed. Objective responses
to a variety of immune therapies have been observed, such as an antibody
against cytotoxic T-lymphocyte protein 4 (CTLA 4) (see reference 66
from Vaughn et al[9]) or BMS-936559, and antiprogrammed death ligand-1
(PDL-1) monoclonal antibody[15] and immune therapies are a promising
area for development. Aberrant DNA methylation is a frequent epigenetic
event in ovarian cancer, and the use of chemotherapy plus epigenetic
modulators such as demethylating agents or histone deacetylase
inhibitors is being studied. The ability to analyze complex genomic data
is rapidly increasing, and ovarian cancer is fairly readily biopsiable.
More than ever, patients with recurrent disease should consider
participation in high quality research trials."
"the addition of PARP inhibitors to chemotherapy in women with recurrent
disease has so far failed to improve survival.[14] Front-line trials
with PARP inhibitors are being planned, and may yield better results"
FROM:
Management of Recurrent EOC: The State of the Art
By Gini F. Fleming, MD1 |
April 15, 2013
---------------------------------------------------------------------------------------
WE ARE GOING TO FURTHER COMMENTS OF THESE NEW OPTIONS AS WE LEARN MORE!
MAY BE WE SHOULD BE ADDING INHIBITORS OF AURORA (s) INSTEAD !
